Treatment of Inflammatory pain using IL-20 Antagonists

Ming-Shi Chang

Treatment of Inflammatory pain using IL-20 Antagonists

Department of Biochemistry and Molecular Biology

Research output: Patent

Abstract

Reducing inflammatory pain in a subject having or being suspected of having an inflammatory pain using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.

Translated title of the contribution	Treatment of Inflammatory pain using IL-20 Antagonists
Original language	English
Patent number	9376490
Publication status	Published - 1800

Fingerprint Dive into the research topics of 'Treatment of Inflammatory pain using IL-20 Antagonists'. Together they form a unique fingerprint.

Cite this

@misc{0799e65a618e435083b319fe7048e82f,

title = "Treatment of Inflammatory pain using IL-20 Antagonists",

abstract = "Reducing inflammatory pain in a subject having or being suspected of having an inflammatory pain using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.",

author = "Ming-Shi Chang",

year = "1800",

language = "English",

type = "Patent",

note = "9376490",

}

TY - PAT

T1 - Treatment of Inflammatory pain using IL-20 Antagonists

AU - Chang, Ming-Shi

PY - 1800

Y1 - 1800

N2 - Reducing inflammatory pain in a subject having or being suspected of having an inflammatory pain using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.

AB - Reducing inflammatory pain in a subject having or being suspected of having an inflammatory pain using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.

M3 - Patent

M1 - 9376490

ER -